Anti-human immunodeficiency virus drug combination strategies (Q45752028)

15 December 2017

review article

1 reference

title

Anti-human immunodeficiency virus drug combination strategies (English)

1 reference

15 December 2017

author

Anne-Mieke Vandamme

series ordinal

1

1 reference

15 December 2017

author name string

K Van Vaerenbergh

series ordinal

2

1 reference

15 December 2017

E De Clercq

series ordinal

3

1 reference

15 December 2017

publication date

1 May 1998

1 reference

15 December 2017

Antiviral Chemistry & Chemotherapy

published in

1 reference

15 December 2017

volume

9

1 reference

15 December 2017

issue

3

1 reference

15 December 2017

page(s)

187-203

1 reference

15 December 2017

Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

The HIV-1 protease as a therapeutic target for AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

HIV-1 protease inhibitors. A review for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Human immunodeficiency virus (HIV) RNA in plasma as the preferred target for therapy in patients with HIV infection: a critique

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

The effects on survival of early treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Viral dynamics of HIV: implications for drug development and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

A controlled trial of zidovudine in primary human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Study Group of the AIDS Clinical Trials Group of the National Inst

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Therapeutic advances: protease inhibitors for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Clonal selection of HIV type 1 variants associated with resistance to foscarnet in vitro: confirmation by molecular evolutionary analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Decay characteristics of HIV-1-infected compartments during combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

HIV viral load markers in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Mother to child transmission of zidovudine-resistant HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Activity of tethered human immunodeficiency virus 1 protease containing mutations in the flap region of one subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Characterization of HIV-1 strains isolated from patients treated with TIBO R82913.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Treatment dilemmas in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Identification, purification, and cell culture assays of retroviral proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Viral dynamics in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Human immunodeficiency virus type-1 reverse transcriptase. Contribution of Met-184 to binding of nucleoside 5'-triphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632029800900301

10.1177/095632029800900301

21 January 2018

Identifiers

DOI

1 reference

15 December 2017

PubMed ID

9875399

1 reference

15 December 2017